COMPANY:

JSR Life Sciences

"KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract with Alanis Therapeutics, Inc. (ATI) for the development of an innovative pre-clinical therapeutic antibody to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) blood cancers."

"Crown Bioscience...announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services...These recognitions affirm the consistent elevation in the quality and precision of Crown Bioscience's laboratory practices, placing the company among a select number of laboratories meeting the stringent CAP and ISO quality standards within preclinical and translational cancer research."

"Medical and Biological Laboratories Co., Ltd...a JSR Life Sciences Company, announced that the MEBGEN™ BRAF 3 Kit, an in vitro diagnostic reagent, was approved for manufacturing and marketing by the Ministry of Health, Labour and Welfare (MHLW) on August 18, 2023, and received national health insurance coverage on November 1, 2023...With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare tumors (solid tumors including histiocytosis and hairy cell leukemia) for which treatment options are limited."

"Medical and Biological Laboratories Co., Ltd...announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022...MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma."